A randomized controlled trial to compare the efficacy and safety of glycopyrronium bromide + salmeterol/fluticasone and tiotropium bromide + salmeterol/fluticasone in chronic obstructive pulmonary disease

Dr. Rajendra Kumar, Dr. Amrendra Kumar*

A randomized controlled trial to compare the efficacy and safety of glycopyrronium bromide + salmeterol/fluticasone and tiotropium bromide + salmeterol/fluticasone in chronic obstructive pulmonary disease

Dr. Rajendra Kumar, Dr. Amrendra Kumar*

Cite this:

[1]

Dr. Rajendra Kumar, Dr. Amrendra Kumar*, “A randomized controlled trial to compare the efficacy and safety of glycopyrronium bromide + salmeterol/fluticasone and tiotropium bromide + salmeterol/fluticasone in chronic obstructive pulmonary disease”, ijmhs, vol. 10, no. 05, pp. 853–857, May 2020.

RIGHTS & PERMISSIONS

Article Views

222

Altmetric

Citations

LEARN ABOUT THESE METRICS

Abstract

Objective: To compare the efficacy and safety of glycopyrronium bromide + salmeterol/
fluticasone and tiotropium bromide + salmeterol/fluticasone in chronic obstructive
pulmonary disease (COPD) in a randomized controlled trial.
Methods: This study was an open labeled randomized controlled trial. Patients diagnosed
with COPD were included in the study. The patients were divided into 2
groups each consisted 75 patients. Group I- COPD patients on Tiotropium bromide
+ Salmeterol/Fluticasone; Group II – COPD patient on Glycopyrronium bromide +
Salmeterol/Fluticasone. A detailed history and clinical examination was done for each
case. Pulmonary Function Test (PFT) was performed at 0, 6 and 12 weeks.
Results: There was no significant (p>0.05) difference in the basic characteristics of
patients between the groups showing comparability of the groups in terms of basic
characteristics. FEV1 was observed to be significantly higher in Group II than Group
I at 12 weeks (p=0.03). There was no significant (p>0.05) difference in PEFR between
the groups at all the time periods. FEF was observed to be significantly higher in
Group II than Group I at 12 weeks (p=0.04). There was no significant (p>0.05)
difference in FEV1/FVC between the groups at all the time periods. MVV was found
to be significantly higher in Group II compared to Group I at 6 weeks (p=0.03) and
12 weeks (p=0.04).
Conclusion: Once-daily GLY demonstrated similar effects to TIO when combined
with SAL/FP in patients with moderate and severe COPD.
Key words: Chronic obstructive pulmonary disease–Glycopyrronium bromide–
Tiotropium bromide–Efficacy–Safety

Content

Part of special issue:

Innovative Journal of Medical and Health Science

Article Metrics by Journal Systems

Citations not available
Readers 222
Download 100

Altmetric Attention score:

Altmetric badge

Share this article

Source

How to Cite

[1]

Issue Vol. 10 No. 05 (2020): Innovative Journal of Medical and Health Science
Section Research Articles

License

All paper submissions must carry the following duly signed by all the authors:
â€œI certify that I have participated sufficiently in the conception and design of this work and the analysis of the data (wherever applicable), as well as the writing of the manuscript, to take public responsibility for it. I believe the manuscript represents valid work. I have reviewed the final version of the manuscript and approve it for publication. Neither has the manuscript nor one with substantially similar content under my authorship been published nor is being considered for publication elsewhere, except as described in an attachment. Furthermore I attest that I shall produce the data upon which the manuscript is based for examination by the editors or their assignees, if requested.â€

Innovative Journal of Medical and Health Sciences

A randomized controlled trial to compare the efficacy and safety of glycopyrronium bromide + salmeterol/fluticasone and tiotropium bromide + salmeterol/fluticasone in chronic obstructive pulmonary disease

Article Views

Altmetric

Citations

Abstract

Special Issue

Article Metrics Graph

Content

Section

Source

License